Unified Protocol treatment for emotional disorders (HiTOP-PRO)
Official title: Investigating the Impact of the Unified Protocol on HiTOP Dimensions and Temperamental Traits in Patients With Emotional Disorders
Run by National Institute of Mental Health, Czech Republic · NCT07557017 · Data updated 2026-11-12
This project will test whether the Unified Protocol—a transdiagnostic cognitive-behavioral therapy—helps adults with emotional disorders feel better than usual care or being on a waitlist.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 90 (estimated) |
| Sponsor | National Institute of Mental Health, Czech Republic Academic / other |
| Locations | 1 site (Prague) |
| Status | Recruiting |
| Started | October 8, 2025 |
| Main results expected | April 30, 2028 |
| Study ends | July 31, 2028 |
| Registry record updated | April 29, 2026 |
| Trial ID | NCT07557017 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18–65 seeking outpatient treatment at NÚDZ who meet ADIS-5 diagnostic criteria for specified emotional disorder categories, can complete Czech-language assessments, and have stable psychotropic medication doses when applicable are ideal candidates.
✕Probably not a fit
People with a current or lifetime psychotic disorder, a current manic/hypomanic episode, or high acute suicide/self-harm risk requiring higher-level care are excluded and unlikely to benefit from this outpatient psychotherapy protocol.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a single-site, randomized, parallel-group trial at the National Institute of Mental Health (NÚDZ) in Prague comparing the manualised Unified Protocol (UP) to treatment as usual (TAU) and a waitlist (WL). Adults seeking outpatient care are screened by telephone and diagnostic eligibility is confirmed with the ADIS-5, then randomized 1:1:1 to UP, TAU, or WL. Outcomes focused on HiTOP-aligned dimensional symptom measures and temperamental/personality traits are collected at baseline and approximately 14 weeks post-randomization, with an optional ~3-month follow-up only in the UP arm. Recruitment is rolling and dependent on clinic throughput and therapist availability.
Why it matters
Potential benefit: If successful, UP could reduce broad dimensional symptoms across emotional disorders and improve related temperamental or personality traits, making one structured treatment useful for multiple diagnoses.
How similar studies have gone: The Unified Protocol has prior randomized-trial evidence showing efficacy across anxiety and depressive disorders, but applying HiTOP-aligned dimensional outcomes and conducting this comparison in routine Czech outpatient care is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: Adults aged 18-65 years. Seeking outpatient treatment at NÚDZ for emotional disorder symptoms. Meets diagnostic eligibility on ADIS-5 for at least one of the following (ICD-10 categories consistent with the protocol): F32, F33, F34, F40, F41, F42, F43, F45, F60, F61. Able to understand and complete study questionnaires and procedures (Czech language). Willing and able to participate in psychotherapy and complete assessments at baseline and post-treatment (14 weeks). If taking psychotropic medication: dose stable for ≥6 weeks prior to enrolment and expected to remain stable during the acute study period where clinically feasible. Provides written informed consent. Exclusion Criteria: Current or lifetime psychotic disorder or current manic/hypomanic episode. High acute suicide risk requiring a higher level of care (e.g., imminent risk, recent serious attempt) or current severe self-harm risk incompatible with outpatient psychotherapy study procedures. Primary substance use disorder requiring specialised treatment or acute intoxication/withdrawal. Severe cognitive impairment or neurodevelopmental/neurological condition that prevents valid consent or completion of study procedures. Concurrent psychological treatment that would conflict with study participation (e.g., starting a new structured psychotherapy during the 14-week study period), unless it constitutes the assigned TAU. Immediate need for intensive treatment (e.g., inpatient admission) at the time of screening. Inability to commit to the study schedule or complete required assessments.
Where it's running
-
National Institute of Mental healh
Prague, Czechia Recruiting
Study contacts
- Study coordinator: Eva Dreyfus, MSc.
- Email: eva.dreyfus@nudz.cz
- Phone: +420283088282
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Emotional distress and immunotherapy response in liver cancer
This project will see if emotional distress changes how well immunotherapy works for people with newly diagnosed, treatment‑naïve liver cancer.
-
Compassion-based family program for adolescents with depression or anxiety
This study tests a six-week compassion-based family program to see if it helps adolescents (ages 12–18) with depression or anxiety and their parents.
-
Unified Protocol for emotional disorders in prison groups
This study tests the Unified Protocol in group sessions to help inmates with anxiety, depression, and related mood issues.
-
Online treatment for emotional disorders in adults with long COVID-19
This study is testing if an online treatment for emotional issues can help adults with long COVID-19 feel better compared to regular care.
-
DBT group program for adults with emotional dysregulation across different diagnoses
This program tries a shortened (4–5 month) DBT group course to see if it improves emotion regulation in adults (18–65) with conditions like borderline personality disorder, bipolar disorder, PTSD, addictions, or eating disorders.
-
Personalized treatment for children with disruptive behavior and their parents
This study is testing a personalized treatment approach for children aged 6-12 with disruptive behavior and their parents to see if it can improve the effectiveness of therapy.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.